Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 7, 2013, Pages 387-395

  Lehtinen, Terhi ^a   Tolonen, Ari ^b   Turpeinen, Miia ^c   Uusitalo, Jouko ^d   Vuorinen, Jouni ^e   Lammintausta, Risto ^f   Pelkonen, Olavi ^c   Scheinin, Mika ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Admescope Ltd   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d Technopolis Oyj   (Finland)

^e 4Pharma Ltd   (Finland)

^f Hormos Medical Ltd   (Finland)

Author keywords

fluconazole; ketoconazole; omeprazole; rifampicin; selective estrogen receptor modulator

Indexed keywords

4 HYDROXYOSPEMIFENE; 4' HYDROXYOSPEMIFENE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUCONAZOLE; FLUVOXAMINE; FURAFYLLINE; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; OSPEMIFENE; PYRIDINE; QUERCETIN; QUINIDINE; RIFAMPICIN; SULFAPHENAZOLE; THIOTEPA; TICLOPIDINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; IC 50; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

FLUCONAZOLE; KETOCONAZOLE; OMEPRAZOLE; RIFAMPICIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; MIDDLE AGED; POSTMENOPAUSE; RIFAMPIN; TAMOXIFEN;

EID: 84885628791     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1853     Document Type: Article

References (17)

1. TM (ospemifene). Full Prescribing Information. Shionogi Inc: Florham Park, NJ, 2013.
2. Santoro N, Komi J,. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133-2142. doi: 10.1111/j.1743-6109. 2009.01335.x.
3. Mac Bride MB, Rhodes DJ, Shuster LT,. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94. doi: 10.4065/mcp.2009.0413.
4. Bachmann GA, Komi JO, and the Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-486. DOI: 10.1097/gme. 0b013e3181c1ac01.
5. Portman DJ, Bachmann GA, Simon JA, and the Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-630.
6. Simon JA, Lin VH, Radovich C, Bachmann GA, The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20: 418-427. DOI: 10.1097.
7. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O,. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004; 18: 152-158. (Pubitemid 38328094)
8. DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK,. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000; 56: 469-475.
9. Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O,. Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact 2013: Epub ahead of print. DOI: 10.1515/dmdi-2013-0016.
10. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M,. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 2007; 37: 1367-1377. (Pubitemid 350146687)
11. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H,. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715. doi: 10.1007/s00204-008-0332-8.
12. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O,. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005; 24: 123-132. (Pubitemid 40051295)
13. European Medicines Agency. Guideline on the Investigation of Drug Interactions. 2010.
14. Morello KC, Wurz GT, DeGregorio MW,. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003; 42: 361-372. (Pubitemid 36433876)
15. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ,. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998; 64: 648-654. (Pubitemid 29011384)
16. Desmarais JE, Looper KJ,. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 2010; 67: 296-308. doi: 10.1016/j.maturitas.2010.08.005.
17. Turpeinen M, Uusitalo J, Lehtinen T, et al,. Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. Int J Mol Sci 2013; 14: 14064-14075.